Retatrutide vs Danuglipron
Head-to-head comparison of Retatrutide and Danuglipron for research applications. Both peptides are studied for Weight Management and Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Retatrutide | Danuglipron |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Oral GLP-1 Agonist (Small Molecule) |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). | Danuglipron is a non-peptide, small-molecule agonist of the GLP-1 receptor. |
| Evidence Rating | B — Phase III / NDA Filed | B — Phase III / NDA Filed |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Phase III (once-daily modified-release formulation for T2D and obesity). Pfizer discontinued the twice-daily formulation development in 2023. |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | Common: nausea (up to 42%), vomiting, diarrhea — significantly higher rates than injectable GLP-1 agonists; High discontinuation rates in Phase II: up to 50% of patients in the highest dose group discontinued, primarily due to GI adverse events |
| Route | Subcutaneous (clinical trial formulation only) | Oral |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | 40–120 mg oral (Phase 2 tested up to 120 mg BID; MR formulation doses TBD) |
| Frequency | Once weekly | Once daily (modified-release) or twice daily (immediate-release) |
| Molecular Weight | N/A | N/A |
| Half-Life | ~6 days (allows once-weekly dosing) | ~6-8 hours (immediate-release formulation) |
Overview
Retatrutide and Danuglipron are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Danuglipron — Mechanism & Evidence
Danuglipron (PF-06882961) is a small-molecule, non-peptide oral GLP-1 receptor agonist developed by Pfizer. NOTE: Danuglipron is NOT a peptide — it is a synthetic small molecule included here for comparison with peptide-based GLP-1 agonists. It is in Phase III development for type 2 diabetes and obesity. Danuglipron was initially studied as a twice-daily formulation, but Pfizer shifted focus to a once-daily modified-release formulation after the twice-daily version showed high discontinuation rates due to GI side effects.
Key claims: Oral small-molecule GLP-1 agonism is feasible; Weight loss in Phase II; HbA1c reduction in T2D.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Danuglipron is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Danuglipron: Common: nausea (up to 42%), vomiting, diarrhea — significantly higher rates than injectable GLP-1 agonists High discontinuation rates in Phase II: up to 50% of patients in the highest dose group discontinued, primarily due to GI adverse events GI tolerability was the primary reason Pfizer discontinued the twice-daily formulation and pivoted to modified-release
Shop Research Peptides
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
BPC-157 5mg
5mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Retatrutide Buy Online: Research Evidence and Limits
Retatrutide is a tri-agonist peptide under investigation, but no peer-reviewed study confirms over-the-counter availability. This article clarifies what evidence supports and what remains unproven.
Retatrutide in Canada: Evidence, Safety, and Access
This article clarifies retatrutide's tri-agonist mechanism, reviews the clinical evidence and its gaps, and outlines legal and safety considerations for Canadian research purchases.
Retatrutide vs Mounjaro: Evidence, Limits, and Tradeoffs
This reference evaluates how far current evidence supports using retatrutide over tirzepatide, highlighting that no head-to-head trial exists and that comparative outcomes remain unmeasured.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe